http://www.oncologyproductguide.com/blog A comprehensive guide to oncology products for medical professionals Fri, 11 Jun 2010 12:00:01 +0000 http://wordpress.org/?v=2.8.2 en hourly 1 http://www.oncologyproductguide.com/blog/2008/04/28/act-ii-study-shows-substantial-tumor-specific-immune-response/ http://www.oncologyproductguide.com/blog/2008/04/28/act-ii-study-shows-substantial-tumor-specific-immune-response/#comments Mon, 28 Apr 2008 18:53:47 +0000 Jim Marino http://www.oncologyproductguide.com/blog/2008/04/28/act-ii-study-shows-substantial-tumor-specific-immune-response/ Data presented by Celldex Therapeutics, a wholly-owned subsidiary of AVANT Immunotherapeutics, from its Phase 2 ACT II study in glioblastoma multiforme (GBM) indicated that temozolomide, the standard chemotherapy agent for this disease, may potentiate the effect of AVANT’s vaccine candidate, CDX-110. All patients vaccinated with CDX-110 in the Phase 2a ACT II extension study showed a tumor-specific immune response, a significant improvement over previous vaccines and over CDX-110 alone.

]]> http://www.oncologyproductguide.com/blog/2008/04/28/act-ii-study-shows-substantial-tumor-specific-immune-response/feed/ 0